AbbVie Inc (ABBV)vsSTRATA Skin Sciences Inc (SSKN)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
SSKN
STRATA Skin Sciences Inc
$0.01
0.00%
HEALTHCARE · Cap: $942,110
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 209654% more annual revenue ($64.39B vs $30.70M). ABBV leads profitability with a 9.8% profit margin vs -20.4%. SSKN appears more attractively valued with a PEG of 0.03. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
SSKN
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for SSKN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.4%
ROE of -158.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : SSKN
The strongest argument for SSKN centers on PEG Ratio, Price/Book. PEG of 0.03 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : SSKN
The primary concerns for SSKN are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while SSKN is a turnaround play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 45/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
STRATA Skin Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
STRATA Skin Sciences, Inc., a medical technology company, develops, markets and markets products for the treatment of dermatological conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company is headquartered in Horsham, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?